Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pralsetinib in Previously Treated RET Fusion-Positive NSCLC
jRCT2021210074Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pralsetinib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Efficacy based on RECIST v1.1 (primary). Started Jun 2022; status: completed.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021210074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210074.